“ mAbxience has a different business model than the majority of big biosimilars producers which have vast sales and marketing capabilities. We have a business-to-business (B2B) model,… ”
In Conversation
“ We have observed big improvements in terms of trust [in biosimilars] from both healthcare professionals and patients [in Spain] in the last few years ”
“ CAR-T is not necessarily the best treatment option for everyone. There could be other second-best options for a certain group of patients. Our point of view… ”
“ We are transforming our view from product-based - selling land, sea or air freight - to understanding what the customer needs are and looking at the… ”
“ While we are not in capital equipment... we foresee the potential for collaboration with hospitals, using new methods of interaction, such as value-based healthcare, to improve… ”
“ Because our clinical and commercial experts live under the same roof, they are able to constantly share real-world knowledge and insights that lead to getting the… ”
“ We continue to be the leader in rare diseases and aspire to be the top company in the gastrointestinal and oncology areas wherever we are present ”
“ The sector is moving towards outcome- and value-based healthcare, of which diagnostics will have a big part to play ”
“ We are assisting in maintaining a high level of employment in the country. We have more than 2,700 employees in Spain ”
“ Spanish healthcare devices are highly competitive and, as a group, we are present in over 60 countries ”
“ The first step into digitalization is to convince our customers to standardise their systems and the way that they collect data. Without this, we cannot progress ”
“ The seawater must be collected from special points in the ocean where there is a lot of phytoplankton, where the marine food chain begins. Because of… ”
